Session Abstract – PMWC 2021 Silicon Valley

The COVID-19 pandemic is driving unprecedented transformation of the global medical research ecosystem through the search for effective new therapeutics that can help ease symptoms and prevent death among COVID-19 patients. This Showcase will include a selected number of companies that are developing breakthrough treatments for COVID-19.

Confirmed Presenting Companies:

 Session Chair Profile

M.D., MPH, Executive Director, Clinical Research, Gilead Sciences

Executive director of clinical research leading the Emerging and Respiratory Viruses group in the Virology therapeutic area at Gilead Sciences, Inc. Anu is an infectious diseases physician with over 15 years of experience in infectious diseases, liver diseases, public health and drug development. In her current role, she oversees development efforts for COVID-19 including Remdesivir. She is the author of over 70 scientific publications and has a passion for rapidly advancing transformative therapies.

 Speaker Profile

J.D., Ph.D., Founder & CEO, Tactical Therapeutics

Dr. Karmali is Founder and CEO, earned her Ph. D in Biochemistry from the University of Newcastle upon Tyne, UK; JD at Rutgers School of Law, and an MBA from Rutgers University, Newark. She worked with Dr. Robert A. Good at the Memorial Sloan-Kettering Cancer Center, NY, and then at Rutgers University in New Brunswick, NJ, as Associate Professor. Her experience includes a translational cancer research program described in more than 100 publications. From 1993 she worked in litigation and transactional practice in Intellectual Property & Technology Law at Pennie & Edmonds, Bryan Cave and Stroock, Stroock & Lavan. She started her Law Firm in 2000 and formed Tactical Therapeutics in 2005 to develop CTO. She holds several patents, has been recognized on the cover of Cancer Research and been awarded the Life- Time Achievement Award by Marquis Who’s Who in 2017.

COVID-19 Treatment Showcase:
Tactical Therapeutics

Tactical Therapeutics is a Clinical stage company located in New York City, Delaware Co (2005); Virtual Business Model; Privately funded; Developing Carboxyamidotriazole Orotate (CTO) for treatment of Cancer starting with the unmet need in Glioblastoma patients. CTO is being repurposed for COVID.

Calcium Signal/Channel Inhibitor to Treat COVID
A first-in-class, oral Calcium signal inhibitor, with a safe toxicity profile and favorable bioavailability inhibits several of the cytokines that are increased in the COVID cytokine storm, in addition to inhibiting the entry and replication of SARS-CoV-2 into VeroE6 cells.